Table 1.

Baseline demographic and health-related characteristics for prostate cancer cases and subcohort members, SELECT case–cohort study

Prostate cancer casesSubcohort non-cases
n = 1,746 (%)n = 3,008 (%)
Age, y, mean (SD)63.5 (6.1)63.3 (6.6)
Race/ethnicity, n (%)
 African American251 (14.4)735 (24.4)
 Hispanic58 (3.3)139 (4.6)
 Caucasian1,406 (80.5)2,083 (69.2)
 Other31 (1.8)51 (1.7)
College graduate, n (%)948 (54.3)1,428 (47.5)
History of benign prostatic hyperplasia, n (%)
 Yes292 (16.7)470 (15.6)
 Missing/unknown142 (8.1)190 (6.3)
Family history of prostate cancer, n (%)506 (29.0)423 (14.1)
History of diabetes, n (%)127 (7.3)386 (12.8)
Height, cm, mean (SD)176.8 (7.4)176.8 (7.5)
BMI, kg/m2, mean (SD)28.5 (4.4)28.8 (4.6)
Smoking status, n (%)
 Lifetime nonsmoker829 (47.5)1,250 (41.6)
 Former smoker821 (47.0)1,497 (49.8)
 Current smoker96 (5.5)261 (8.7)
Trial supplementation arm, n (%)
 α-Tocopherol only479 (27.4)765 (25.4)
 Selenomethionine only437 (25.0)749 (24.9)
 α-Tocopherol and selenomethionine424 (24.3)753 (25.0)
 Placebo406 (23.3)741 (24.6)
Dietary intake/day, mean (SD)
 Energy, kcal2,352 (1,081)2,312 (1,185)
 Total fat, g94.2 (52.1)93.6 (56.4)
 Calcium, mg1,059 (597)1,012 (604)
 Vitamin D (calciferol), μg7.1 (5.0)6.8 (5.0)
 Vitamin E, IU18.1 (12)17.9 (14.4)
Supplemental vitamin E use before trial, n (%)501 (28.7)860 (28.6)
Plasma biochemical measures, mean (SD)
 Alpha-tocopherol (AT), mg/L14.0 (5.3)13.6 (5.6)
 Gamma-tocopherol (GT), mg/L1.9 (1.1)2.0 (1.2)
 AT:GT molar ratio12.5 (17.0)11.6 (16.0)
 Cholesterol, mg/dL203 (37)200 (38)
PSA (μg/mL), n (%)
 <1.00130 (7.4)1,330 (44.2)
 1.00–1.99464 (26.6)1,039 (34.5)
 2.00–2.99587 (33.6)420 (14.0)
 ≥3.00564 (32.3)219 (7.3)
PSA (μg/mL), median (inter-quartile range)2.4 (1.7–3.2)1.1 (0.6–1.8)